Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc. (EIKN) priced its initial public offering on Feb 5, 2026 at $18.00 per share, raising $381.2M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $971.7M. J.P. Morgan was lead-left underwriter, joined by Morgan Stanley, BofA Securities and Cantor and others. Covington & Burling advised the company and Davis Polk advised the underwriters.

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing medicines for serious unmet medical needs. Its initial focus is oncology, where it is advancing a pipeline of drug candidates, combining biology research with advanced engineering.

Status

IPO

Ticker

EIKN

Exchange

Nasdaq Global Select

Priced

Feb 5, 2026

IPO price

$18.00

Raised

$381.2M

Market cap at IPO price

$971.7M

First filed

Jan 9, 2026

Underwriters

J.P. Morgan, Morgan Stanley, BofA Securities, Cantor and Mizuho

Company counsel

Covington & Burling

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.